 Cholesterol, LDL
"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 3 | 3 | | 2012 | 1 | 3 | 4 | | 2014 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Puri R, Mehta V, Duell PB, Iyengar SS, Yusuf J, Dalal J, Narasingan SN, Kalra D, Kapoor A, Pradhan A, Mukhopadhyay S, Vijayaraghavan K, Aggarwal R, Muruganathan A, Prabhakar D, Misra S, Shetty S, Kasliwal RR, Bansal M, Khanna N, Khan A, Melinkeri RP, Kumar S, Chakraborty RN, Bardoloi N, Sahoo P, Vinayagam P, Modi R, Nanda R, Wong ND. Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India. J Clin Lipidol. 2022 May-Jun; 16(3):261-271.
-
Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
-
Kalra DK. Bridging the Racial Disparity Gap in Lipid-Lowering Therapy. J Am Heart Assoc. 2021 01 05; 10(1):e019533.
-
Nambi V, Sikand G, Kalra D, Vijayaraghavan K. Low-density lipoprotein cholesterol goals in the secondary prevention of cardiovascular diseases in the Indian population-Is 30 the new 70? J Clin Lipidol. 2020 Mar - Apr; 14(2):173-175.
-
Lamar M, Durazo-Arvizu RA, Rodriguez CJ, Kaplan RC, Perera MJ, Cai J, Espinoza Giacinto RA, González HM, Daviglus ML. Associations of Lipid Levels and Cognition: Findings from the Hispanic Community Health Study/Study of Latinos. J Int Neuropsychol Soc. 2020 03; 26(3):251-262.
-
Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga SR, Maggioni AP, Paizis G, Tomic R, Catapano AL. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018 04; 271:120-127.
-
März W, Dippel FW, Theobald K, Gorcyca K, Iorga SR, Ansell D. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis. 2018 01; 268:99-107.
-
Costello BT, Silverman ER, Doukky R, Braun LT, Aggarwal NT, Deng Y, Li Y, Lundberg G, Williams KA, Volgman AS. Lipoprotein(a) and Increased Cardiovascular Risk in Women. Clin Cardiol. 2016 Feb; 39(2):96-102.
-
Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
-
Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15; 210(10):1549-54.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|